Ken Griffin Essa Pharma Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$4.45 - $7.1 $76,540 - $122,120	17,200 Added 452.63%	21,000 $127,000
Q2 2024 Aug 14, 2024	SELL	$4.63 - $8.42 $45,837 - $83,358	-9,900 Reduced 72.26%	3,800 $19,000
Q1 2024 May 15, 2024	BUY	$6.17 - $10.65 $75,274 - $129,930	12,200 Added 813.33%	13,700 $116,000
Q4 2023 Feb 14, 2024	SELL	$2.74 - $7.35 $16,166 - $43,365	-5,900 Reduced 79.73%	1,500 $9,000
Q3 2023 Nov 14, 2023	SELL	$2.65 - $3.31 $5,300 - $6,620	-2,000 Reduced 21.28%	7,400 $22,000
Q2 2023 Aug 14, 2023	SELL	$2.6 - $3.34 $102,700 - $131,930	-39,500 Reduced 80.78%	9,400 $25,000
Q1 2023 May 15, 2023	BUY	$2.56 - $3.55 $18,432 - $25,560	7,200 Added 17.27%	48,900 $145,000
Q4 2022 Feb 14, 2023	BUY	$1.5 - $4.82 $62,550 - $200,994	41,700 New	41,700 $105,000

35.1M

15.8K

21K

Ticker EPIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,073,100
Market Cap $75.4M
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreem...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.